NCT00384280View on ClinicalTrials.gov

Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Healthy
Interventions
DRUG

Rifampin

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00384280 - Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796 | Biotech Hunter | Biotech Hunter